SCM
TENX icon

Stonepine Capital Management’s Tenax Therapeutics TENX Stock Holding History

Stonepine Capital Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.6M Buy
975,200
+963,316
+8,106% +$13M 6.24% 4
2025
Q4 		$145K Buy
+11,884
New +$103K 0.11% 62
2024
Q4 		– Sell
-50,000
Closed -$173K – 56
2024
Q3 		$173K Buy
+50,000
New +$181K 0.11% 36

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Stonepine Capital Management's TENX Position: Q1 2026 in Review

Stonepine Capital Management increased its Tenax Therapeutics (TENX) stake by 8,106% in Q1 2026, buying an estimated $13M and bringing the position to 975,200 shares worth $15.6M. The position accounts for 6.24% of the portfolio, ranked #4.

Stonepine Capital Management first reported a position in TENX in Q3 2024 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Stonepine Capital Management held 975,200 shares of Tenax Therapeutics worth $15.6M as of Q1 2026.
  • Stonepine Capital Management bought 963,316 Tenax Therapeutics shares in Q1 2026, an estimated $13M.
  • Tenax Therapeutics made up 6.24% of Stonepine Capital Management's portfolio in Q1 2026, its #4 holding.
  • Stonepine Capital Management first reported a position in Tenax Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.